Strontium ranelate (PROTELOS(®)) is a relatively novel drug, currently approved in Europe for the treatment of postmenopausal osteoporosis. Strontium ranelate is the first agent of a new therapeutic class in osteoporosis, capable of both promoting bone formation and, to a lesser extent, inhibiting bone resorption.

Osteoporosis is a chronic disease characterized by low bone mass caused by increased bone turnover and impaired bone microarchitecture. In treatment, we use antiresorptive or anabolic drugs, which usually have a unidirectional effect, i.e., they inhibit the activity of osteoclasts or stimulate the effect of osteoblasts. Strontium ranelate is an …

The review on strontium ranelate for preventing and treating postmenopausal osteoporosis (2) appears to violate these standards. One of the trials included in the review, the TROPOS trial, was a pivotal trial submitted to the European Medicines Agency (EMEA) within the application for marketing authorisation, which was …

The review covers historical and last decade's scientific literature on the biological and clinical role of strontium (Sr) and strontium ranelate (Sr RAN). It enrols the description of the main effects of Sr on supportive tissue, its proven and possible morphopathogenetical mechanisms and the interaction with the bone, and especially …

Strontium ranelate is a new orally active agent consisting of two atoms of stable strontium and an organic moiety (ranelic acid). It stimulates the formation of new bone tissue and decreases bone ...

In our review, we found moderate-quality evidence that glucosamine and chondroitin had statistically significant but marginally small structural and symptomatic effects, in addition to favorable safety profiles. ... Strontium ranelate presented promising structural modifying effects in our study and is believed to suppress subchondral bone ...

We review here today's evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy ...

The novelty of strontium ranelate compared to other treatments for osteoporosis is its unique effect on bone: it simultaneously promotes bone formation by osteoblasts and inhibits bone resorption by osteoclasts. Besides affecting bone cells, treatment with strontium ranelate also has a direct effect on the mineralized bone matrix.

In vitro studies have suggested that strontium ranelate enhances osteoblast cell replication and activity. Simultaneously, strontium ranelate dose-dependently inhibits osteoclast activity. In vivo studies indicate that strontium ranelate stimulates bone formation and inhibits bone resorption and prevents bone loss and/or promotes bone gain.

The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually …

Strontium Ranelate A Review of its Use in the Treatment of Postmenopausal Osteoporosis Emma D. Deeks and Sohita Dhillon Adis, a Wolters Kluwer Business, Auckland, New Zealand Various sections of the manuscript reviewed by: M. Kleerekoper, Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan,

Strontium ranelate is a medicine with evidenced effects on the risk of fractures. The heterogeneity of strontium distribution in bone, quality of bone mineral crystals in young bone packets on bone surfaces formed during strontium ranelate administration, and activation of the calcium sensing receptor may, at least partially, explain the beneficial …

Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while activating gene expression in osteoblasts. While its exact mechanism of action is unknown, one hypothesis is that both anabolic and anti-catabolic activities may involve antagonizing ...

The percentage increases in BMD in the strontium ranelate group are consistent with 1-year results from two pivotal fracture studies conducted with strontium ranelate in postmenopausal women with osteoporosis [1, 2].Strontium ranelate was associated with a 22% greater increase in BMD at the lumbar spine (p = 0.033) and 23% …

Strontium ranelate is a divalent strontium salt of ranelic acid that is capable of increasing bon … This is a review of the pharmacology of strontium …

Strontium ranelate rebalances bone turnover in favor of improved bone geometry, cortical thickness, trabecular bone morphology and intrinsic bone tissue quality, which translates into enhanced bone strength. This review describes the mechanism of the strontium ranelate action and its effects on bone mineral density, bone turnover, and ...

Strontium Ranelate and Strontium Chloride Supplementation Influence on Bone Microarchitecture and Bone Turnover Markers—A Preliminary Study, ... A Review and Update, Life, 12, 6, (903), ...

Cianferroti L, Asta FD, Brandi ML (2013) A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskel Dis 5(3):127–139 31. Cacoub P1 Descamps V, Meyer O, Speirs C, Belissa-Mathiot P, Musette P (2013) Drug rash with eosinophilia and systemic symptoms …

Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, …

This review discusses the long-term, sustained antifracture efficacy and safety profile of strontium ranelate, which has been proved in the results of the preplanned phase III registrative trials at 5 years and recently confirmed in open-label extension studies of the initial trials, starting from the basic in vitro and in vivo pharmacologic ...

Strontium ranelate is a newly developed drug that acts as an effective antiosteoporotic therapy in postmenopausal women with osteoporosis. In contrast to other available treatments for osteoporosis, strontium ranelate induces opposite effects on bone resorption and formation. ... The purpose of this review is to summarize the experimental …

The effects of strontium ranelate on bone mineral density (BMD) have also been positive [14,15,[25][26] [27] [28]. However, since the atomic number of strontium is greater than calcium (38 vs. 20 ...

Due to the wide availability of anti-osteoporotic drugs whose primary end-points are to improve BMD and to reduce fracture risk, the secondary end-point of these drugs is now …

Strontium ranelate is a medication used for the management of severe osteoporosis in high-risk postmenopausal women and adult men. Generic Name Strontium ranelate DrugBank Accession Number DB09267 Background. Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have …

The review shows that: There is silver level evidence () that for treatment of osteoporosis in women after menopause, 2 g of strontium ranelate daily over 3 years decreases fractures in the spine and slightly decreases fractures not in the spine. Most women do not have side effects that would cause them to stop taking ...

Strontium ranelate: SYRCLE: Systematic Review Centre for Laboratory animal Experimentation: Authors' contributions. CRS, CBS, and RSN performed the search, conducted the review, and drafted the manuscript. RACM and EM-Jr assisted in assessing the studies, carried out the editing of the manuscript, and helped in the manuscript drafting.

STrontium Ranelate reduced the alveolar bone loss in non-treated animals and presented no standout benefits over the conventional forms of treating EP and showed a significantly more organized pattern of the connective tissue and alveolars bone structure than EP-SRP/SR. Expand. 1. [PDF] 2 Excerpts.

The current recommendations for the prescription of strontium ranelate result from regulatory re-evaluation procedures for the agent. These began in April 2013, when the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) recommended a re-assessment of the overall benefit-risk ratio …

4/7/2015. Condition: Osteoporosis. Overall rating 5.0. Effectiveness. Ease of Use. Satisfaction. 18% increase in spine, 8% increase in hip after two years of taking Vitamin Code Grow Bone consisting of two separate bottles, one of raw calcium and the other of strontium, taken at least four hours apart.

A review of strontium ranelate and its effect on DXA scans. 2007 Apr-Jun;10 (2):113-9. doi: 10.1016/j.jocd.2007.01.002. Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures. This review article examines the evidence for the ...